

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-64) CAROTUXIMAB

PRONUNCIATION kar" oh tux' i mab

THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human endoglin) (human-*Mus musculus* monoclonal TRC105 heavy chain), disulfide with human-*Mus musculus* monoclonal TRC105 κ-chain, dimer
2. Immunoglobulin G1-kappa, anti-(human endoglin (CD105 antigen)); human mouse chimeric monoclonal antibody; γ1 heavy chain (1-448) [mouse VH (*Mus musculus* IGHV6-6*01 (98%) –(IGHD)-IGHJ2*01 (87%)) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01 (119-448)] (221-213')-disulfide with kappa light chain (1'-213') [mouse V-KAPPA (*Mus musculus* IGKV4-72*01 (99%) – IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')], dimer (227-227":230-230")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

| | | | | | |
|-------------|------------|------------|------------|------------|-----|
| EVKLEESGGG | LVQPGGSMKL | SCAASGFTFS | DAWMDWVRQS | PEKGLEWVAE | 50 |
| IRSKASNHAT | YYAESVKGRF | TISRDDSKSS | VYLQMNSLRA | EDTGIYYCTR | 100 |
| WRRFFDSWGQ | GTTLTVSSAS | TKGPSVFPLA | PSSKSTSGGT | AALGCLVKDY | 150 |
| FPEPVTVSWN | SGALTSVHT | FPAVLQSSGL | YSLSSVVTVP | SSSLGTQTYI | 200 |
| CNVNHNKPSNT | KVDKKVEPKS | CDKTHTCPPC | PAPELLGGPS | VFLFPPKPKD | 250 |
| TLMISRTPPEV | TCVVVDVSH | DPEVKFNWYV | DGVEVHNAKT | KPREEQYNST | 300 |
| YRVVSVLTVL | HQDWLNKEY | KCKVSNKALP | APIEKTISKA | KGQPREPQVY | 350 |
| TLPPSRDEL | KNQVSLTCLV | KGFYPSDIAV | EWESNGQPEN | NYKTTTPVLD | 400 |
| SDGSFFLYSK | LTVDKSRWQQ | GNVFSCSVH | EALHNHYTQK | SLSLSPGK | 448 |

Light chain

| | | | | | |
|------------|------------|------------|------------|------------|------|
| QIVLSQSPAI | LSASPGKVT | MTCRASSVS | YMHWYQKPG | SSPKPIYAT | 50' |
| SNLASGVPVR | FSGSGGTSY | SLTISRVEAE | DAATYYCQW | SSNPLTFGAG | 100' |
| TKLELKRIVA | APSVFIFPPS | DEQLKSGTAS | VVCLLNNFYP | REAKVQWKVD | 150' |
| NALQSGNSQE | SVTEQDSKDS | TYSLSSTLTL | SKADYEKHKV | YACEVTHQGL | 200' |
| SSPVTKSFNR | GEC | | | | 213' |

Disulfide bridges

| | | | | | | | |
|----------|---------------|---------|-------------|-----------|---------------|---------|-----------|
| 22-98 | 22"-98" | 23'-87' | 23'''-87''' | 133'-193' | 133'''-193''' | 145-201 | 145"-201" |
| 213'-221 | 213'''-221''' | 227-27" | 230-230" | 262-322 | 262'''-322''' | 368-426 | 368"-426" |

Glycosylation sites (N)

Asn-298 Asn-298"

MOLECULAR FORMULA C₆₄₂₀H₉₉₂₂N₁₇₁₈O₂₀₁₀S₄₆ (non-glycosylated)

MOLECULAR WEIGHT 144.8 kDa (non-glycosylated)

TRADEMARK None as yet

| | |
|----------------------------|-----------------------------|
| SPONSOR | TRACON Pharmaceuticals Inc. |
| CODE DESIGNATIONS | TRC-105, c-SN6j |
| <u>CAS</u> REGISTRY NUMBER | 1268714-50-6 |
| UNII | YB2EWE6139 |
| WHO NUMBER | 10244 |

gbk